Andreas Eugen Busch
Co-Chair of Scientific Advisory BoardDr. Andreas Eugen Busch, also known as Andy, Ph.D., is Independent Outside Director of Astellas Pharma Inc. from June 19, 2026. Dr. Busch is Independent Director of Sun Pharmaceutical Industries Limited from May 12, 2026. Dr. Busch was an Independent Outside Director of Astellas Pharma Inc. from June 2025 until May 29, 2026. Dr. Busch served as Chief Innovation Officer at Absci Corporation since October 2022 until March 31, 2026 and serves as its Co-Chair of Scientific Advisory Board since March 31, 2026 and serves as its Member of Scientific Advisory Board since 2024 and served as its Director since October 2022 until November 2022. Dr. Busch served as Independent Director of Absci Corporation since March 17, 2022 until September 2022. He served as Vice-Chairman of the Supervisory Board at Centogene N.V. since 18th February 2022 until December 12, 2023 and served as Member Ad Interim of the Supervisory Board since 2022. Dr. Busch served as Chief Scientific Officer at Cyclerion Therapeutics, Inc. since January 1, 2021 until September 30, 2022 and served as its Chief Innovation Officer and Head of the Innovation Center since April 9, 2019, until January 1, 2021. He serves as Member of Scientific Advisory Board at Arix Bioscience plc from June 2020 till June 2022. Dr. Busch served as the Member of the Advisory Board at VI Partners AG since joining in 2018. He served as Head of Research and Development and Chief Scientific Officer at Shire Pharmaceuticals (Shire plc) since January 1, 2018. He served as Head of Global Drug Discovery at Bayer HealthCare AG since February 1, 2007, until 2017. During his years at Bayer, he has served roles of increasing responsibility within it, including Senior Vice President, Head Discovery Europe at Bayer HealthCare and Executive Vice President, Global Head Drug Discovery. Dr. Busch was responsible for the Schering drug discovery integration, the overall R&D strategy and enforced the improvement of Bayer's research productivity. Prior to joining Bayer, Dr. Busch was Global Head of Cardiovascular Research at Hoechst and Sanofi-Aventis. Prior to that, he led independent research groups as a Heisenberg Fellow at the University of Tübingen and the Max-Planck-Institute for experimental Medicine in Göttingen. Dr. Busch has served as a Member of Board of Management of Bayer Pharma AG and of its subsidiary Bayer Schering Pharma AG since February 1, 2007. Dr. Busch serves as the Chairman of the Supervisory Board of Icon Genetics, Germany. Dr. Busch is a Member of several Supervisory and Scientific Boards, including the German Cancer Research Center, the University of Tübingen, the Max-Delbrück-Center and the Max-Planck-Institute of Molecular Genetics. He also holds the title of Extraordinary Professor of Pharmacology at the Johann Wolfgang Goethe-University in Frankfurt, Germany. He served as a Member of Supervisory Board at Bayer CropScience AG. He serves as a Member of the Scientific Advisory Board of Robert Koch Foundation and Schering Foundation. He received Doctor of Philosophy in Pharmacology at the Johann Wolfgang Goethe University in 1989. Dr. Busch served as Chief Innovation Officer of Absci GmbH since September 2022. Dr. Busch held various positions at Bayer AG, including Executive Vice President and Head of Drug Discovery for Bayer Animal Health from January 2016 to December 2017.
Positions
- Company NameAbsci CorporationStock CodeABSIPositionCo-Chair of Scientific Advisory BoardColleagues
- SMSean McClainFounder, CEO, President & Director
- ZJZachariah JonassonChief Business Officer & CFO
- TBTodd BedrickSenior VP & Chief Accounting Officer
- AKAlexander KhanCVP of Finance & Head of Investor Relations
- SWShelby WalkerChief Legal Officer
- KKKaren K. McGinnisLead Independent Director
- DADaniel A. RabinovitsjIndependent Director
- FAFrançois Adrianus van HoutenIndependent Director
